APO Research
Talk to an analyst

APO RESEARCH · REPORT

Topoisomerase I Inhibitors

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global Topoisomerase I Inhibitors Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

21 December 2025198 pages

Choose your research edition.

Industry ResearchTopoisomerase I Inhibitors Industry Research Report 2026133 pages · $2,950 USDIndustry Growth & TrendsGlobal Topoisomerase I Inhibitors Industry Growth and Trends Forecast to 2032111 pages · $3,450 USDMarket StructureGlobal Topoisomerase I Inhibitors Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032198 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Topoisomerase I Inhibitors Market Outlook and Growth Opportunities 2026200 pages · $4,250 USDMarket Analysis & ForecastGlobal Topoisomerase I Inhibitors Market Analysis and Forecast 2026-2032200 pages · $4,950 USD

Market perspective

The global Topoisomerase I Inhibitors market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.

The US & Canada market for Topoisomerase I Inhibitors is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Topoisomerase I Inhibitors is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Topoisomerase I Inhibitors is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for Topoisomerase I Inhibitors is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Topoisomerase I Inhibitors include Chong Kun Dang Pharmaceutical, Grand Pharmaceutical, Teva Pharmaceutical Industries, CSPC Pharmaceutical, Novartis AG, Kelun Pharmaceutical, Pfizer, Hengrui Pharmaceuticals and Daiichi Sankyo, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Topoisomerase I Inhibitors market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Topoisomerase I Inhibitors and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Topoisomerase I Inhibitors sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Topoisomerase I Inhibitors market size, projected growth trends, production technologies, key applications, and end-use industries.

Topoisomerase I Inhibitors Segment by Company

Chong Kun Dang Pharmaceutical

Grand Pharmaceutical

Teva Pharmaceutical Industries

CSPC Pharmaceutical

Novartis AG

Kelun Pharmaceutical

Pfizer

Hengrui Pharmaceuticals

Daiichi Sankyo

Yakult Honsha

Summit Medical

Servier Laboratories (Aust)

Nippon Kayaku

MOH Holdings

Meitheal Pharmaceuticals

Les Laboratoires Servier SAS

Ipsen SA

Eton Pharmaceuticals

Topoisomerase I Inhibitors Segment by Type

Camptothecin Derivatives

Non-camptothecin

Topoisomerase I Inhibitors Segment by Application

Hospital

Clinic

Others

Topoisomerase I Inhibitors Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Colombia

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Topoisomerase I Inhibitors market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Topoisomerase I Inhibitors and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Topoisomerase I Inhibitors.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Topoisomerase I Inhibitors market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).

Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Topoisomerase I Inhibitors manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales of Topoisomerase I Inhibitors in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 7: Revenue of Topoisomerase I Inhibitors in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. Topoisomerase I Inhibitors Industry Trends Table 2. Topoisomerase I Inhibitors Industry Drivers Table 3. Topoisomerase I Inhibitors Industry Opportunities and Challenges Table 4. Topoisomerase I Inhibitors Industry Restraints Table 5. Global Topoisomerase I Inhibitors Revenue by Manufacturers (US$ Million) & (2021-2026) Table 6. Global Topoisomerase I Inhibitors Revenue Market Share by Manufacturers (2021-2026) Table 7. Global Topoisomerase I Inhibitors Sales by Manufacturers (k units) & (2021-2026) Table 8. Global Topoisomerase I Inhibitors Sales Market Share by Manufacturers Table 9. Global Topoisomerase I Inhibitors Average Sales Price (US$/unit) of Manufacturers (2021-2026) Table 10. Global Topoisomerase I Inhibitors Industry Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 11. Global Topoisomerase I Inhibitors Key Manufacturers Manufacturing Sites & Headquarters Table 12. Global Topoisomerase I Inhibitors Manufacturers, Product Type & Application Table 13. Global Topoisomerase I Inhibitors Manufacturers Establishment Date Table 14. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 15. Global Topoisomerase I Inhibitors by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 16. Major Manufacturers of Camptothecin Derivatives Table 17. Major Manufacturers of Non-camptothecin Table 18. Global Topoisomerase I Inhibitors Sales by Type 2021 VS 2025 VS 2032 (k units) Table 19. Global Topoisomerase I Inhibitors Sales by Type (2021-2026) & (k units) Table 20. Global Topoisomerase I Inhibitors Sales by Type (2027-2032) & (k units) Table 21. Global Topoisomerase I Inhibitors Sales Market Share by Type (2021-2026) Table 22. Global Topoisomerase I Inhibitors Sales Market Share by Type (2027-2032) Table 23. Global Topoisomerase I Inhibitors Revenue by Type 2021 VS 2025 VS 2032 (k units) Table 24. Global Topoisomerase I Inhibitors Revenue by Type (2021-2026) & (k units) Table 25. Global Topoisomerase I Inhibitors Revenue by Type (2027-2032) & (k units) Table 26. Global Topoisomerase I Inhibitors Revenue Market Share by Type (2021-2026) Table 27. Global Topoisomerase I Inhibitors Revenue Market Share by Type (2027-2032) Table 28. Major Manufacturers of Hospital Table 29. Major Manufacturers of Clinic Table 30. Major Manufacturers of Others Table 31. Global Topoisomerase I Inhibitors Sales by Application 2021 VS 2025 VS 2032 (k units) Table 32. Global Topoisomerase I Inhibitors Sales by Application (2021-2026) & (k units) Table 33. Global Topoisomerase I Inhibitors Sales by Application (2027-2032) & (k units) Table 34. Global Topoisomerase I Inhibitors Sales Market Share by Application (2021-2026) Table 35. Global Topoisomerase I Inhibitors Sales Market Share by Application (2027-2032) Table 36. Global Topoisomerase I Inhibitors Revenue by Application 2021 VS 2025 VS 2032 (k units) Table 37. Global Topoisomerase I Inhibitors Revenue by Application (2021-2026) & (k units) Table 38. Global Topoisomerase I Inhibitors Revenue by Application (2027-2032) & (k units) Table 39. Global Topoisomerase I Inhibitors Revenue Market Share by Application (2021-2026) Table 40. Global Topoisomerase I Inhibitors Revenue Market Share by Application (2027-2032) Table 41. Global Topoisomerase I Inhibitors Sales by Region: 2021 VS 2025 VS 2032 (k units) Table 42. Global Topoisomerase I Inhibitors Sales by Region (2021-2026) & (k units) Table 43. Global Topoisomerase I Inhibitors Sales Market Share by Region (2021-2026) Table 44. Global Topoisomerase I Inhibitors Sales Forecasted by Region (2027-2032) & (k units) Table 45. Global Topoisomerase I Inhibitors Sales Forecasted Market Share by Region (2027-2032) Table 46. North America Topoisomerase I Inhibitors Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k units) Table 47. North America Topoisomerase I Inhibitors Sales by Country (2021-2026) & (k units) Table 48. North America Topoisomerase I Inhibitors Sales by Country (2027-2032) & (k units) Table 49. Europe Topoisomerase I Inhibitors Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k units) Table 50. Europe Topoisomerase I Inhibitors Sales by Country (2021-2026) & (k units) Table 51. Europe Topoisomerase I Inhibitors Sales by Country (2027-2032) & (k units) Table 52. Asia Pacific Topoisomerase I Inhibitors Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k units) Table 53. Asia Pacific Topoisomerase I Inhibitors Sales by Country (2021-2026) & (k units) Table 54. Asia Pacific Topoisomerase I Inhibitors Sales by Country (2027-2032) & (k units) Table 55. South America, Middle East and Africa Topoisomerase I Inhibitors Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k units) Table 56. South America, Middle East and Africa Topoisomerase I Inhibitors Sales by Country (2021-2026) & (k units) Table 57. South America, Middle East and Africa Topoisomerase I Inhibitors Sales by Country (2027-2032) & (k units) Table 58. Global Topoisomerase I Inhibitors Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 59. Global Topoisomerase I Inhibitors Revenue by Region (2021-2026) & (US$ Million) Table 60. Global Topoisomerase I Inhibitors Revenue by Region (2027-2032) & (US$ Million) Table 61. Global Topoisomerase I Inhibitors Revenue Market Share by Region (2021-2026) Table 62. Global Topoisomerase I Inhibitors Revenue Market Share by Region (2027-2032) Table 63. Chong Kun Dang Pharmaceutical Company Information Table 64. Chong Kun Dang Pharmaceutical Business Overview Table 65. Chong Kun Dang Pharmaceutical Topoisomerase I Inhibitors Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 66. Chong Kun Dang Pharmaceutical Topoisomerase I Inhibitors Product Portfolio Table 67. Chong Kun Dang Pharmaceutical Recent Development Table 68. Grand Pharmaceutical Company Information Table 69. Grand Pharmaceutical Business Overview Table 70. Grand Pharmaceutical Topoisomerase I Inhibitors Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 71. Grand Pharmaceutical Topoisomerase I Inhibitors Product Portfolio Table 72. Grand Pharmaceutical Recent Development Table 73. Teva Pharmaceutical Industries Company Information Table 74. Teva Pharmaceutical Industries Business Overview Table 75. Teva Pharmaceutical Industries Topoisomerase I Inhibitors Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 76. Teva Pharmaceutical Industries Topoisomerase I Inhibitors Product Portfolio Table 77. Teva Pharmaceutical Industries Recent Development Table 78. CSPC Pharmaceutical Company Information Table 79. CSPC Pharmaceutical Business Overview Table 80. CSPC Pharmaceutical Topoisomerase I Inhibitors Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 81. CSPC Pharmaceutical Topoisomerase I Inhibitors Product Portfolio Table 82. CSPC Pharmaceutical Recent Development Table 83. Novartis AG Company Information Table 84. Novartis AG Business Overview Table 85. Novartis AG Topoisomerase I Inhibitors Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 86. Novartis AG Topoisomerase I Inhibitors Product Portfolio Table 87. Novartis AG Recent Development Table 88. Kelun Pharmaceutical Company Information Table 89. Kelun Pharmaceutical Business Overview Table 90. Kelun Pharmaceutical Topoisomerase I Inhibitors Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 91. Kelun Pharmaceutical Topoisomerase I Inhibitors Product Portfolio Table 92. Kelun Pharmaceutical Recent Development Table 93. Pfizer Company Information Table 94. Pfizer Business Overview Table 95. Pfizer Topoisomerase I Inhibitors Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 96. Pfizer Topoisomerase I Inhibitors Product Portfolio Table 97. Pfizer Recent Development Table 98. Hengrui Pharmaceuticals Company Information Table 99. Hengrui Pharmaceuticals Business Overview Table 100. Hengrui Pharmaceuticals Topoisomerase I Inhibitors Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 101. Hengrui Pharmaceuticals Topoisomerase I Inhibitors Product Portfolio Table 102. Hengrui Pharmaceuticals Recent Development Table 103. Daiichi Sankyo Company Information Table 104. Daiichi Sankyo Business Overview Table 105. Daiichi Sankyo Topoisomerase I Inhibitors Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 106. Daiichi Sankyo Topoisomerase I Inhibitors Product Portfolio Table 107. Daiichi Sankyo Recent Development Table 108. Yakult Honsha Company Information Table 109. Yakult Honsha Business Overview Table 110. Yakult Honsha Topoisomerase I Inhibitors Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 111. Yakult Honsha Topoisomerase I Inhibitors Product Portfolio Table 112. Yakult Honsha Recent Development Table 113. Summit Medical Company Information Table 114. Summit Medical Business Overview Table 115. Summit Medical Topoisomerase I Inhibitors Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 116. Summit Medical Topoisomerase I Inhibitors Product Portfolio Table 117. Summit Medical Recent Development Table 118. Servier Laboratories (Aust) Company Information Table 119. Servier Laboratories (Aust) Business Overview Table 120. Servier Laboratories (Aust) Topoisomerase I Inhibitors Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 121. Servier Laboratories (Aust) Topoisomerase I Inhibitors Product Portfolio Table 122. Servier Laboratories (Aust) Recent Development Table 123. Nippon Kayaku Company Information Table 124. Nippon Kayaku Business Overview Table 125. Nippon Kayaku Topoisomerase I Inhibitors Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 126. Nippon Kayaku Topoisomerase I Inhibitors Product Portfolio Table 127. Nippon Kayaku Recent Development Table 128. MOH Holdings Company Information Table 129. MOH Holdings Business Overview Table 130. MOH Holdings Topoisomerase I Inhibitors Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 131. MOH Holdings Topoisomerase I Inhibitors Product Portfolio Table 132. MOH Holdings Recent Development Table 133. Meitheal Pharmaceuticals Company Information Table 134. Meitheal Pharmaceuticals Business Overview Table 135. Meitheal Pharmaceuticals Topoisomerase I Inhibitors Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 136. Meitheal Pharmaceuticals Topoisomerase I Inhibitors Product Portfolio Table 137. Meitheal Pharmaceuticals Recent Development Table 138. Les Laboratoires Servier SAS Company Information Table 139. Les Laboratoires Servier SAS Business Overview Table 140. Les Laboratoires Servier SAS Topoisomerase I Inhibitors Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 141. Les Laboratoires Servier SAS Topoisomerase I Inhibitors Product Portfolio Table 142. Les Laboratoires Servier SAS Recent Development Table 143. Ipsen SA Company Information Table 144. Ipsen SA Business Overview Table 145. Ipsen SA Topoisomerase I Inhibitors Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 146. Ipsen SA Topoisomerase I Inhibitors Product Portfolio Table 147. Ipsen SA Recent Development Table 148. Eton Pharmaceuticals Company Information Table 149. Eton Pharmaceuticals Business Overview Table 150. Eton Pharmaceuticals Topoisomerase I Inhibitors Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 151. Eton Pharmaceuticals Topoisomerase I Inhibitors Product Portfolio Table 152. Eton Pharmaceuticals Recent Development Table 153. Key Raw Materials Table 154. Raw Materials Key Suppliers Table 155. Topoisomerase I Inhibitors Distributors List Table 156. Topoisomerase I Inhibitors Customers List Table 157. Research Programs/Design for This Report Table 158. Authors List of This Report Table 159. Secondary Sources Table 160. Primary Sources List of Figures Figure 1. Topoisomerase I Inhibitors Product Image Figure 2. Global Topoisomerase I Inhibitors Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Topoisomerase I Inhibitors Market Size (2021-2032) & (US$ Million) Figure 4. Global Topoisomerase I Inhibitors Sales (2021-2032) & (k units) Figure 5. Global Topoisomerase I Inhibitors Average Price (US$/unit) & (2021-2032) Figure 6. Global Top 5 and 10 Topoisomerase I Inhibitors Players Market Share by Revenue in 2025 Figure 7. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 8. Camptothecin Derivatives Image Figure 9. Non-camptothecin Image Figure 10. Global Topoisomerase I Inhibitors Sales by Type (2021 VS 2025 VS 2032) & (k units) Figure 11. Global Topoisomerase I Inhibitors Sales Market Share 2021 VS 2025 VS 2032 Figure 12. Global Topoisomerase I Inhibitors Sales Market Share by Type (2021-2032) Figure 13. Global Topoisomerase I Inhibitors Revenue by Type (2021 VS 2025 VS 2032) & (k units) Figure 14. Global Topoisomerase I Inhibitors Revenue Market Share 2021 VS 2025 VS 2032 Figure 15. Global Topoisomerase I Inhibitors Revenue Market Share by Type (2021-2032) Figure 16. Hospital Image Figure 17. Clinic Image Figure 18. Others Image Figure 19. Global Topoisomerase I Inhibitors Sales by Application (2021 VS 2025 VS 2032) & (k units) Figure 20. Global Topoisomerase I Inhibitors Sales Market Share 2021 VS 2025 VS 2032 Figure 21. Global Topoisomerase I Inhibitors Sales Market Share by Application (2021-2032) Figure 22. Global Topoisomerase I Inhibitors Revenue by Application (2021 VS 2025 VS 2032) & (k units) Figure 23. Global Topoisomerase I Inhibitors Revenue Market Share 2021 VS 2025 VS 2032 Figure 24. Global Topoisomerase I Inhibitors Revenue Market Share by Application (2021-2032) Figure 25. North America Topoisomerase I Inhibitors Sales and Growth Rate (2021-2032) & (k units) Figure 26. North America Topoisomerase I Inhibitors Sales Market Share by Country (2021-2032) Figure 27. U.S. Topoisomerase I Inhibitors Sales and Growth Rate (2021-2032) & (k units) Figure 28. Canada Topoisomerase I Inhibitors Sales and Growth Rate (2021-2032) & (k units) Figure 29. Mexico Topoisomerase I Inhibitors Sales and Growth Rate (2021-2032) & (k units) Figure 30. Europe Topoisomerase I Inhibitors Sales and Growth Rate (2021-2032) & (k units) Figure 31. Europe Topoisomerase I Inhibitors Sales Market Share by Country (2021-2032) Figure 32. Germany Topoisomerase I Inhibitors Sales and Growth Rate (2021-2032) & (k units) Figure 33. France Topoisomerase I Inhibitors Sales and Growth Rate (2021-2032) & (k units) Figure 34. U.K. Topoisomerase I Inhibitors Sales and Growth Rate (2021-2032) & (k units) Figure 35. Italy Topoisomerase I Inhibitors Sales and Growth Rate (2021-2032) & (k units) Figure 36. Netherlands Topoisomerase I Inhibitors Sales and Growth Rate (2021-2032) & (k units) Figure 37. Asia Pacific Topoisomerase I Inhibitors Sales and Growth Rate (2021-2032) & (k units) Figure 38. Asia Pacific Topoisomerase I Inhibitors Sales Market Share by Country (2021-2032) Figure 39. China Topoisomerase I Inhibitors Sales and Growth Rate (2021-2032) & (k units) Figure 40. Japan Topoisomerase I Inhibitors Sales and Growth Rate (2021-2032) & (k units) Figure 41. South Korea Topoisomerase I Inhibitors Sales and Growth Rate (2021-2032) & (k units) Figure 42. Southeast Asia Topoisomerase I Inhibitors Sales and Growth Rate (2021-2032) & (k units) Figure 43. India Topoisomerase I Inhibitors Sales and Growth Rate (2021-2032) & (k units) Figure 44. Australia Topoisomerase I Inhibitors Sales and Growth Rate (2021-2032) & (k units) Figure 45. South America, Middle East and Africa Topoisomerase I Inhibitors Sales and Growth Rate (2021-2032) & (k units) Figure 46. South America, Middle East and Africa Topoisomerase I Inhibitors Sales Market Share by Country (2021-2032) Figure 47. Brazil Topoisomerase I Inhibitors Sales and Growth Rate (2021-2032) & (k units) Figure 48. South Africa Topoisomerase I Inhibitors Sales and Growth Rate (2021-2032) & (k units) Figure 49. Saudi Arabia Topoisomerase I Inhibitors Sales and Growth Rate (2021-2032) & (k units) Figure 50. Turkey Topoisomerase I Inhibitors Sales and Growth Rate (2021-2032) & (k units) Figure 51. Argentina Topoisomerase I Inhibitors Sales and Growth Rate (2021-2032) & (k units) Figure 52. UAE Topoisomerase I Inhibitors Sales and Growth Rate (2021-2032) & (k units) Figure 53. Egypt Topoisomerase I Inhibitors Sales and Growth Rate (2021-2032) & (k units) Figure 54. Chile Topoisomerase I Inhibitors Sales and Growth Rate (2021-2032) & (k units) Figure 55. Global Topoisomerase I Inhibitors Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 56. Global Topoisomerase I Inhibitors Revenue Market Share by Region in Percentage: 2025 Versus 2032 Figure 57. North America Topoisomerase I Inhibitors Revenue (2021-2032) & (US$ Million) Figure 58. North America Topoisomerase I Inhibitors Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 59. Europe Topoisomerase I Inhibitors Revenue (2021-2032) & (US$ Million) Figure 60. Europe Topoisomerase I Inhibitors Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 61. Asia-Pacific Topoisomerase I Inhibitors Revenue (2021-2032) & (US$ Million) Figure 62. Asia-Pacific Topoisomerase I Inhibitors Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 63. South America, Middle East and Africa Topoisomerase I Inhibitors Revenue (2021-2032) & (US$ Million) Figure 64. South America, Middle East and Africa Topoisomerase I Inhibitors Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 65. Topoisomerase I Inhibitors Value Chain Figure 66. Manufacturing Cost Structure Figure 67. Topoisomerase I Inhibitors Production Mode & Process Figure 68. Direct Comparison with Distribution Share Figure 69. Distributors Profiles Figure 70. Years Considered Figure 71. Research Process Figure 72. Key Executives Interviewed

Scope & coverage.

Types
  • Camptothecin Derivatives
  • Non-camptothecin
Applications
  • Hospital
  • Clinic
  • Others
Companies covered
  • Chong Kun Dang Pharmaceutical
  • Grand Pharmaceutical
  • Teva Pharmaceutical Industries
  • CSPC Pharmaceutical
  • Novartis AG
  • Kelun Pharmaceutical
  • Pfizer
  • Hengrui Pharmaceuticals
  • Daiichi Sankyo
  • Yakult Honsha
  • Summit Medical
  • Servier Laboratories (Aust)
  • Nippon Kayaku
  • MOH Holdings
  • Meitheal Pharmaceuticals
  • Les Laboratoires Servier SAS
  • Ipsen SA
  • Eton Pharmaceuticals

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Topoisomerase I Inhibitors Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Topoisomerase I Inhibitors Market Size Estimates and Forecasts (2021-2032)
  4. 1.4 Global Topoisomerase I Inhibitors Sales Estimates and Forecasts (2021-2032)
  5. 1.5 Global Topoisomerase I Inhibitors Market Average Price (2021-2032)
  6. 1.6 Assumptions and Limitations
  7. 1.7 Study Goals and Objectives
2 Global Topoisomerase I Inhibitors Market Dynamics
  1. 2.1 Topoisomerase I Inhibitors Industry Trends
  2. 2.2 Topoisomerase I Inhibitors Industry Drivers
  3. 2.3 Topoisomerase I Inhibitors Industry Opportunities and Challenges
  4. 2.4 Topoisomerase I Inhibitors Industry Restraints
3 Topoisomerase I Inhibitors Market by Manufacturers
  1. 3.1 Global Topoisomerase I Inhibitors Revenue by Manufacturers (2021-2026)
  2. 3.2 Global Topoisomerase I Inhibitors Sales by Manufacturers (2021-2026)
  3. 3.3 Global Topoisomerase I Inhibitors Average Sales Price by Manufacturers (2021-2026)
  4. 3.4 Global Topoisomerase I Inhibitors Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Topoisomerase I Inhibitors Key Manufacturers Manufacturing Sites & Headquarters
  6. 3.6 Global Topoisomerase I Inhibitors Manufacturers, Product Type & Application
  7. 3.7 Global Topoisomerase I Inhibitors Manufacturers Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Topoisomerase I Inhibitors Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Topoisomerase I Inhibitors Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Topoisomerase I Inhibitors Tier 1, Tier 2, and Tier 3
4 Topoisomerase I Inhibitors Market by Type
  1. 4.1 Topoisomerase I Inhibitors Type Introduction
  2. 4.1.1 Camptothecin Derivatives
  3. 4.1.2 Non-camptothecin
  4. 4.2 Global Topoisomerase I Inhibitors Sales by Type
  5. 4.2.1 Global Topoisomerase I Inhibitors Sales by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Topoisomerase I Inhibitors Sales by Type (2021-2032)
  7. 4.2.3 Global Topoisomerase I Inhibitors Sales Market Share by Type (2021-2032)
  8. 4.3 Global Topoisomerase I Inhibitors Revenue by Type
  9. 4.3.1 Global Topoisomerase I Inhibitors Revenue by Type (2021 VS 2025 VS 2032)
  10. 4.3.2 Global Topoisomerase I Inhibitors Revenue by Type (2021-2032)
  11. 4.3.3 Global Topoisomerase I Inhibitors Revenue Market Share by Type (2021-2032)
5 Topoisomerase I Inhibitors Market by Application
  1. 5.1 Topoisomerase I Inhibitors Application Introduction
  2. 5.1.1 Hospital
  3. 5.1.2 Clinic
  4. 5.1.3 Others
  5. 5.2 Global Topoisomerase I Inhibitors Sales by Application
  6. 5.2.1 Global Topoisomerase I Inhibitors Sales by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Topoisomerase I Inhibitors Sales by Application (2021-2032)
  8. 5.2.3 Global Topoisomerase I Inhibitors Sales Market Share by Application (2021-2032)
  9. 5.3 Global Topoisomerase I Inhibitors Revenue by Application
  10. 5.3.1 Global Topoisomerase I Inhibitors Revenue by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global Topoisomerase I Inhibitors Revenue by Application (2021-2032)
  12. 5.3.3 Global Topoisomerase I Inhibitors Revenue Market Share by Application (2021-2032)
6 Global Topoisomerase I Inhibitors Sales by Region
  1. 6.1 Global Topoisomerase I Inhibitors Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Topoisomerase I Inhibitors Sales by Region (2021-2032)
  3. 6.2.1 Global Topoisomerase I Inhibitors Sales by Region (2021-2026)
  4. 6.2.2 Global Topoisomerase I Inhibitors Sales Forecasted by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Topoisomerase I Inhibitors Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  7. 6.3.2 North America Topoisomerase I Inhibitors Sales by Country (2021-2032)
  8. 6.3.3 U.S.
  9. 6.3.4 Canada
  10. 6.3.5 Mexico
  11. 6.4 Europe
  12. 6.4.1 Europe Topoisomerase I Inhibitors Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  13. 6.4.2 Europe Topoisomerase I Inhibitors Sales by Country (2021-2032)
  14. 6.4.3 Germany
  15. 6.4.4 France
  16. 6.4.5 U.K.
  17. 6.4.6 Italy
  18. 6.4.7 Netherlands
  19. 6.5 Asia Pacific
  20. 6.5.1 Asia Pacific Topoisomerase I Inhibitors Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  21. 6.5.2 Asia Pacific Topoisomerase I Inhibitors Sales by Country (2021-2032)
  22. 6.5.3 China
  23. 6.5.4 Japan
  24. 6.5.5 South Korea
  25. 6.5.6 Southeast Asia
  26. 6.5.7 India
  27. 6.5.8 Australia
  28. 6.6 South America, Middle East and Africa
  29. 6.6.1 South America, Middle East and Africa Topoisomerase I Inhibitors Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  30. 6.6.2 South America, Middle East and Africa Topoisomerase I Inhibitors Sales by Country (2021-2032)
  31. 6.6.3 Brazil
  32. 6.6.4 South Africa
  33. 6.6.5 Saudi Arabia
  34. 6.6.6 Turkey
  35. 6.6.6 Argentina
  36. 6.6.6 UAE
  37. 6.6.6 Egypt
  38. 6.6.6 Chile
7 Global Topoisomerase I Inhibitors Revenue by Region
  1. 7.1 Global Topoisomerase I Inhibitors Revenue by Region
  2. 7.1.1 Global Topoisomerase I Inhibitors Revenue by Region: 2021 VS 2025 VS 2032
  3. 7.1.2 Global Topoisomerase I Inhibitors Revenue by Region (2021-2026)
  4. 7.1.3 Global Topoisomerase I Inhibitors Revenue by Region (2027-2032)
  5. 7.1.4 Global Topoisomerase I Inhibitors Revenue Market Share by Region (2021-2032)
  6. 7.2 North America
  7. 7.2.1 North America Topoisomerase I Inhibitors Revenue (2021-2032)
  8. 7.2.2 North America Topoisomerase I Inhibitors Revenue Share by Country: 2021 VS 2025 VS 2032
  9. 7.3 Europe
  10. 7.3.1 Europe Topoisomerase I Inhibitors Revenue (2021-2032)
  11. 7.3.2 Europe Topoisomerase I Inhibitors Revenue Share by Country: 2021 VS 2025 VS 2032
  12. 7.4 Asia-Pacific
  13. 7.4.1 Asia-Pacific Topoisomerase I Inhibitors Revenue (2021-2032)
  14. 7.4.2 Asia-Pacific Topoisomerase I Inhibitors Revenue Share by Country: 2021 VS 2025 VS 2032
  15. 7.5 South America, Middle East and Africa
  16. 7.5.1 South America, Middle East and Africa Topoisomerase I Inhibitors Revenue (2021-2032)
  17. 7.5.2 South America, Middle East and Africa Topoisomerase I Inhibitors Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
  1. 8.1 Chong Kun Dang Pharmaceutical
  2. 8.1.1 Chong Kun Dang Pharmaceutical Company Information
  3. 8.1.2 Chong Kun Dang Pharmaceutical Business Overview
  4. 8.1.3 Chong Kun Dang Pharmaceutical Topoisomerase I Inhibitors Sales, Price, Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Chong Kun Dang Pharmaceutical Topoisomerase I Inhibitors Product Portfolio
  6. 8.1.5 Chong Kun Dang Pharmaceutical Recent Developments
  7. 8.2 Grand Pharmaceutical
  8. 8.2.1 Grand Pharmaceutical Company Information
  9. 8.2.2 Grand Pharmaceutical Business Overview
  10. 8.2.3 Grand Pharmaceutical Topoisomerase I Inhibitors Sales, Price, Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Grand Pharmaceutical Topoisomerase I Inhibitors Product Portfolio
  12. 8.2.5 Grand Pharmaceutical Recent Developments
  13. 8.3 Teva Pharmaceutical Industries
  14. 8.3.1 Teva Pharmaceutical Industries Company Information
  15. 8.3.2 Teva Pharmaceutical Industries Business Overview
  16. 8.3.3 Teva Pharmaceutical Industries Topoisomerase I Inhibitors Sales, Price, Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Teva Pharmaceutical Industries Topoisomerase I Inhibitors Product Portfolio
  18. 8.3.5 Teva Pharmaceutical Industries Recent Developments
  19. 8.4 CSPC Pharmaceutical
  20. 8.4.1 CSPC Pharmaceutical Company Information
  21. 8.4.2 CSPC Pharmaceutical Business Overview
  22. 8.4.3 CSPC Pharmaceutical Topoisomerase I Inhibitors Sales, Price, Revenue and Gross Margin (2021-2026)
  23. 8.4.4 CSPC Pharmaceutical Topoisomerase I Inhibitors Product Portfolio
  24. 8.4.5 CSPC Pharmaceutical Recent Developments
  25. 8.5 Novartis AG
  26. 8.5.1 Novartis AG Company Information
  27. 8.5.2 Novartis AG Business Overview
  28. 8.5.3 Novartis AG Topoisomerase I Inhibitors Sales, Price, Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Novartis AG Topoisomerase I Inhibitors Product Portfolio
  30. 8.5.5 Novartis AG Recent Developments
  31. 8.6 Kelun Pharmaceutical
  32. 8.6.1 Kelun Pharmaceutical Company Information
  33. 8.6.2 Kelun Pharmaceutical Business Overview
  34. 8.6.3 Kelun Pharmaceutical Topoisomerase I Inhibitors Sales, Price, Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Kelun Pharmaceutical Topoisomerase I Inhibitors Product Portfolio
  36. 8.6.5 Kelun Pharmaceutical Recent Developments
  37. 8.7 Pfizer
  38. 8.7.1 Pfizer Company Information
  39. 8.7.2 Pfizer Business Overview
  40. 8.7.3 Pfizer Topoisomerase I Inhibitors Sales, Price, Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Pfizer Topoisomerase I Inhibitors Product Portfolio
  42. 8.7.5 Pfizer Recent Developments
  43. 8.8 Hengrui Pharmaceuticals
  44. 8.8.1 Hengrui Pharmaceuticals Company Information
  45. 8.8.2 Hengrui Pharmaceuticals Business Overview
  46. 8.8.3 Hengrui Pharmaceuticals Topoisomerase I Inhibitors Sales, Price, Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Hengrui Pharmaceuticals Topoisomerase I Inhibitors Product Portfolio
  48. 8.8.5 Hengrui Pharmaceuticals Recent Developments
  49. 8.9 Daiichi Sankyo
  50. 8.9.1 Daiichi Sankyo Company Information
  51. 8.9.2 Daiichi Sankyo Business Overview
  52. 8.9.3 Daiichi Sankyo Topoisomerase I Inhibitors Sales, Price, Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Daiichi Sankyo Topoisomerase I Inhibitors Product Portfolio
  54. 8.9.5 Daiichi Sankyo Recent Developments
  55. 8.10 Yakult Honsha
  56. 8.10.1 Yakult Honsha Company Information
  57. 8.10.2 Yakult Honsha Business Overview
  58. 8.10.3 Yakult Honsha Topoisomerase I Inhibitors Sales, Price, Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Yakult Honsha Topoisomerase I Inhibitors Product Portfolio
  60. 8.10.5 Yakult Honsha Recent Developments
  61. 8.11 Summit Medical
  62. 8.11.1 Summit Medical Company Information
  63. 8.11.2 Summit Medical Business Overview
  64. 8.11.3 Summit Medical Topoisomerase I Inhibitors Sales, Price, Revenue and Gross Margin (2021-2026)
  65. 8.11.4 Summit Medical Topoisomerase I Inhibitors Product Portfolio
  66. 8.11.5 Summit Medical Recent Developments
  67. 8.12 Servier Laboratories (Aust)
  68. 8.12.1 Servier Laboratories (Aust) Company Information
  69. 8.12.2 Servier Laboratories (Aust) Business Overview
  70. 8.12.3 Servier Laboratories (Aust) Topoisomerase I Inhibitors Sales, Price, Revenue and Gross Margin (2021-2026)
  71. 8.12.4 Servier Laboratories (Aust) Topoisomerase I Inhibitors Product Portfolio
  72. 8.12.5 Servier Laboratories (Aust) Recent Developments
  73. 8.13 Nippon Kayaku
  74. 8.13.1 Nippon Kayaku Company Information
  75. 8.13.2 Nippon Kayaku Business Overview
  76. 8.13.3 Nippon Kayaku Topoisomerase I Inhibitors Sales, Price, Revenue and Gross Margin (2021-2026)
  77. 8.13.4 Nippon Kayaku Topoisomerase I Inhibitors Product Portfolio
  78. 8.13.5 Nippon Kayaku Recent Developments
  79. 8.14 MOH Holdings
  80. 8.14.1 MOH Holdings Company Information
  81. 8.14.2 MOH Holdings Business Overview
  82. 8.14.3 MOH Holdings Topoisomerase I Inhibitors Sales, Price, Revenue and Gross Margin (2021-2026)
  83. 8.14.4 MOH Holdings Topoisomerase I Inhibitors Product Portfolio
  84. 8.14.5 MOH Holdings Recent Developments
  85. 8.15 Meitheal Pharmaceuticals
  86. 8.15.1 Meitheal Pharmaceuticals Company Information
  87. 8.15.2 Meitheal Pharmaceuticals Business Overview
  88. 8.15.3 Meitheal Pharmaceuticals Topoisomerase I Inhibitors Sales, Price, Revenue and Gross Margin (2021-2026)
  89. 8.15.4 Meitheal Pharmaceuticals Topoisomerase I Inhibitors Product Portfolio
  90. 8.15.5 Meitheal Pharmaceuticals Recent Developments
  91. 8.16 Les Laboratoires Servier SAS
  92. 8.16.1 Les Laboratoires Servier SAS Company Information
  93. 8.16.2 Les Laboratoires Servier SAS Business Overview
  94. 8.16.3 Les Laboratoires Servier SAS Topoisomerase I Inhibitors Sales, Price, Revenue and Gross Margin (2021-2026)
  95. 8.16.4 Les Laboratoires Servier SAS Topoisomerase I Inhibitors Product Portfolio
  96. 8.16.5 Les Laboratoires Servier SAS Recent Developments
  97. 8.17 Ipsen SA
  98. 8.17.1 Ipsen SA Company Information
  99. 8.17.2 Ipsen SA Business Overview
  100. 8.17.3 Ipsen SA Topoisomerase I Inhibitors Sales, Price, Revenue and Gross Margin (2021-2026)
  101. 8.17.4 Ipsen SA Topoisomerase I Inhibitors Product Portfolio
  102. 8.17.5 Ipsen SA Recent Developments
  103. 8.18 Eton Pharmaceuticals
  104. 8.18.1 Eton Pharmaceuticals Company Information
  105. 8.18.2 Eton Pharmaceuticals Business Overview
  106. 8.18.3 Eton Pharmaceuticals Topoisomerase I Inhibitors Sales, Price, Revenue and Gross Margin (2021-2026)
  107. 8.18.4 Eton Pharmaceuticals Topoisomerase I Inhibitors Product Portfolio
  108. 8.18.5 Eton Pharmaceuticals Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Topoisomerase I Inhibitors Value Chain Analysis
  2. 9.1.1 Topoisomerase I Inhibitors Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Topoisomerase I Inhibitors Production Mode & Process
  6. 9.2 Topoisomerase I Inhibitors Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Topoisomerase I Inhibitors Distributors
  9. 9.2.3 Topoisomerase I Inhibitors Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources
    8. 11.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst